News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Agios Pharmaceuticals Publication Identifies First Potent Inhibitors of Mutant IDH1 that Lower Tumor Oncometabolite



10/11/2012 9:57:42 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, announced today a recent publication that highlights the discovery of the first potent inhibitors of mutant isocitrate dehydrogenase (IDH) that lower tumor 2-HG in vivo. The article “Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo” was published in American Chemical Society Medicinal Chemistry Letters online on September 17, 2012 and in the October 2012 issue.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES